HQL-79

HQL-79 is a selective inhibitor of hematopoietic prostaglandin D (PGD) synthase. Structurally, it is a synthetic tetrazole compound originally prepared as a possible antihistamine. Subsequent evaluation in models of allergy and asthma demonstrates the HQL-79 is orally available, and inhibits the synthesis of PGD2 (Cay-12010). HQL-79 is thus a likely lead compound for the preparation of potent, selective hematopoietic PGD synthase inhibitors.Formal Name: 4-(diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl]-piperidine. CAS Number: 162641-16-9. Molecular Formula: C22H27N5O. Formula Weight: 377.5. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: Methanol: 2.5 mg/ml. SMILES: c1ccc(cc1)C(OC1CCN(CCCc2nnn[nH]2)CC1)c1ccccc1. InChi Code: InChI=1S/C22H27N5O/c1-3-8-18(9-4-1)22(19-10-5-2-6-11-19)28-20-13-16-27(17-14-20)15-7-12-21-23-25-26-24-21/h1-6,8-11,20,22H,7,12-17H2,(H,23,24,25,26). InChi Key: TZQGXAHOROZEKN-UHFFFAOYSA-N.